Skip to main content
SearchLoginLogin or Signup

Reviews of "Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility"

Reviewers: Carmen Abate (Università degli Studi di Bari) | 📗📗📗📗◻️ • Kenji Hashimoto (Chiba University) | 📗📗📗📗◻️

Published onMar 29, 2021
Reviews of "Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility"
key-enterThis Pub is a Review of
Inhibition of SARS-CoV-2 infection in human cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoskeleton architecture and contractility
Description

ABSTRACTHeart dysfunction, represented by conditions such as myocarditis and arrhythmia, has been reported in COVID-19 patients. Therapeutic strategies focused on the cardiovascular system, however, remain scarce. The Sigma-1 receptor (S1R) has been recently proposed as a therapeutic target because its inhibition reduces SARS-CoV-2 replication. To investigate the role of S1R in SARS-CoV-2 infection in the heart, we used human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CM) as an experimental model. Here we show that the S1R antagonist NE-100 decreases SARS-CoV-2 infection and viral replication in hiPSC-CMs. Also, NE-100 reduces cytokine release and cell death associated with infection. Because S1R is involved in cardiac physiology, we investigated the effects of NE-100 in cardiomyocyte morphology and function. We show that NE-100 compromises cytoskeleton integrity and reduces beating frequency, causing contractile impairment. These results show that targeting S1R to challenge SARS-CoV-2 infection may be a useful therapeutic strategy but its detrimental effects in vivo on cardiac function should not be ignored.

To read the original manuscript, click the link above.

Summary of Reviews: This preprint uses iPS-derived cardiomyocytes to investigate the role of Sigma-1 Receptor (S1R) during SARS-CoV-2 infection and finds S1R antagonism reduces SARS-CoV-2 replication at the expense of cardiomyocyte function. Reviewers deem these claims reliable.

Reviewer 1 (Carmen Abate) | 📗📗📗📗◻️

Reviewer 2 (Kenji Hashimoto) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.

Comments
0
comment
No comments here
Why not start the discussion?